Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bangalore, N.
Right arrow Articles by Bhargava, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bangalore, N.
Right arrow Articles by Bhargava, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:271-274, 2001
© 2001 European Society for Medical Oncology

case-report

Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: Case report and review of the literature

N. Bangalore1, P. Bhargava2,, M. J. Hawkins1 and P. Bhargava1,

1Division of Hematology/Oncology Lombardi Cancer Center
2Department of Pathology, Georgetown University Medical Center Washington, DC, USA

Lombardi Cancer Center-Podium B Georgetown University Medical Center 3800 Reservoir Road NW Washington, DC 20007 USA

The sarcomatoid variant of renal-cell carcinoma (SRCC), a clinically aggressive subtype of renal parenchymal tumors, is typically resistant to systemic treatments and carries a poor prognosis. The authors report a case of a 57-year-old male with advanced SRCC who had a durable complete response after MAID (mesna, adriamycin, ifosfamide and dacarbazine) chemotherapy, and remains free of disease four years after completing treatment. To the authors' knowledge, this is the first report of a remission from MAID chemotherapy in SRCC. A review of published literature revealed occasional responses after systemic chemotherapy. Notably, all responses were seen with doxorubicin containing regimens, suggesting that doxorubicin is a critical component in chemotherapy regimens for SRCC.

complete response, doxorubicin-based chemotherapy, MAID, sarcomatoid renal-cell carcinoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A. R. Golshayan, S. George, D. Y. Heng, P. Elson, L. S. Wood, T. M. Mekhail, J. A. Garcia, H. Aydin, M. Zhou, R. M. Bukowski, et al.
Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy
J. Clin. Oncol., January 10, 2009; 27(2): 235 - 241.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.